Cargando…
A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer
BACKGROUND: The high cost and the long time required to bring drugs into commerce is driving efforts to repurpose FDA approved drugs—to find new uses for which they weren’t intended, and to thereby reduce the overall cost of commercialization, and shorten the lag between drug discovery and availabil...
Autores principales: | Chen, Hsiao-Rong, Sherr, David H., Hu, Zhenjun, DeLisi, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967295/ https://www.ncbi.nlm.nih.gov/pubmed/27475327 http://dx.doi.org/10.1186/s12920-016-0212-7 |
Ejemplares similares
-
Using Functional Signatures to Identify Repositioned Drugs for Breast, Myelogenous Leukemia and Prostate Cancer
por: Shigemizu, Daichi, et al.
Publicado: (2012) -
Evaluation and integration of cancer gene classifiers: identification and ranking of plausible drivers
por: Liu, Yang, et al.
Publicado: (2015) -
Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
por: Kim, In-Wha, et al.
Publicado: (2019) -
Gene annotation and network inference by phylogenetic profiling
por: Wu, Jie, et al.
Publicado: (2006) -
Drug Repositioning for Effective Prostate Cancer Treatment
por: Turanli, Beste, et al.
Publicado: (2018)